Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. - Wikidata - wikimedia - TriplyDB

Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.

Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.

http://www.wikidata.org/entity/Q43228809

about

Risk Factors for Acquired Rifamycin and Isoniazid Resistance: A Systematic Review and Meta-Analysis Diagnosis & treatment of tuberculosis in HIV co-infected patients.Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis The impact of isoniazid resistance on the treatment outcomes of smear positive re-treatment tuberculosis patients in the state of Andhra Pradesh, India Nine- to Twelve-Month Anti-Tuberculosis Treatment Is Associated with a Lower Recurrence Rate than 6-9-Month Treatment in Human Immunodeficiency Virus-Infected Patients: A Retrospective Population-Based Cohort Study in Taiwan What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis.Efficacy and safety of thrice weekly DOTS in tuberculosis patients with and without HIV co-infection: an observational study Year in review 2011: respiratory infections, tuberculosis, pleural diseases, bronchoscopic intervention and imaging Directly-observed intermittent therapy versus unsupervised daily regimen during the intensive phase of antituberculosis therapy in HIV infected patients Isoniazid-resistant tuberculosis: a cause for concern?Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary tuberculosis in India and the potential role of IL-6 in prediction.Novel developments in the epidemic of human immunodeficiency virus and tuberculosis coinfection Rifampin monoresistant tuberculosis and HIV comorbidity in California, 1993-2008: a retrospective cohort study Duration of anti-tuberculosis therapy and timing of antiretroviral therapy initiation: association with mortality in HIV-related tuberculosis.Clinical response of newly diagnosed HIV seropositive & seronegative pulmonary tuberculosis patients with the RNTCP Short Course regimen in Pune, India.Treatment of drug-resistant tuberculosis.Medication adherence and its determinants among patients on concomitant tuberculosis and antiretroviral therapy in South west ethiopia.Natural History and Factors Associated with Early and Delayed Mortality in HIV-Infected Patients Treated of Tuberculosis under Directly Observed Treatment Short-Course Strategy: A Prospective Cohort Study in India.New drugs and regimens for treatment of TB.Optimal Duration of Daily Antituberculosis Therapy before Switching to DOTS Intermittent Therapy to Reduce Mortality in HIV Infected Patients: A Duration-Response Analysis Using Restricted Cubic Splines.Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans.Clinical Correlates and Drug Resistance in HIV-Infected and -Uninfected Pulmonary Tuberculosis Patients in South India.Tuberculosis and HIV co-infection: screening and treatment strategies.Update in tuberculosis and nontuberculous mycobacterial disease 2010.Update in tuberculosis and nontuberculous mycobacterial disease 2011.An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection.Effect of Intermittency on Treatment Outcomes in Pulmonary Tuberculosis: An Updated Systematic Review and Metaanalysis.Long-term Mortality of Patients With Tuberculous Meningitis in New York City: A Cohort Study.TB-HIV co-infection: a catastrophic comradeship.Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy.Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.Acquired rifamycin mono-resistance and dosing schedules in HIV-related tuberculosis.Reply to Daskapan et al.Does oxidative stress contribute to adverse outcomes in HIV-associated TB?Tuberculosis and HIV Coinfection.Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV: A Randomized Clinical Trial.

P2860

Q26781111-EE0545C7-0470-4261-B895-E08303D7F49C Q26991633-61E38461-C2BB-4618-8064-557D813613E9 Q28069032-262E91DE-949F-4F62-938E-449404373682 Q28534364-7C929FC8-D673-4F07-BD1E-9E671483B5F3 Q28551297-7C8283F0-DA91-4AD7-84F0-B80266CD9163 Q30249635-53049196-0574-4B41-B584-D0143E9C199C Q31141015-D469FB45-C317-4563-BE7C-C205CAC4B15A Q33790711-4E61B081-BBA0-4ABF-ABFF-04ADE90E5EC0 Q33809970-69E22A6A-87DB-4BEE-B039-D610D65ADB7D Q33820505-8E78BBB5-8A7B-4831-9D3F-9E1D3962B928 Q34730629-9ABCFC2B-087A-4079-AE12-60F7D4227881 Q34914625-17601495-6D57-42EE-AFC5-5A49D27D90D5 Q34974157-1D96C7B1-3257-422C-9E5B-F9395103DB49 Q34997183-5DA4B2B7-549B-4D6F-A00A-FB5183AFFC1A Q35062838-DF032152-F601-4B72-AF35-97AC18BD277E Q35187176-584CCC23-A574-4F7C-A774-FF8504153588 Q35811045-181AC23F-37C4-48E0-A98B-A93872533957 Q36505791-E0AC0AE9-6D58-4B35-887B-C636210F6462 Q36825354-0A961505-D20A-4211-80E4-9AB40898B11A Q36979305-0DBEED0F-0CF7-4EC3-931C-7CC01A9D6C4C Q37120003-996D24C7-2F50-4591-A3A4-C770B3E1D8C9 Q37304534-33816847-A784-4BCF-9557-95B4FDC8B5C5 Q37895251-66B3C82A-4B78-419D-AEDA-AA24F16240B3 Q37902000-BB0D20A5-D828-46C2-A3B8-D4D8F1F11B26 Q38019488-A13DAECD-AE88-451D-9097-98C33039DA9D Q38028326-25A4BE47-5D1B-4DA5-932C-4F3FEB8D085C Q38958884-A50E6FC5-A3CF-4EB8-8A2F-E0E0746AF04F Q39032302-3A87FAFC-F718-4C90-AEFF-2C927A0C5F13 Q39826708-82232508-4DB9-4957-896E-1D5DCBC01686 Q42198014-EB2FA64B-26FF-450A-B19A-9557C449B2DA Q42615157-B03DA121-93A2-4E95-9195-C65A74E8B47C Q43825254-2808B245-F6B1-4B2A-A84C-BC5E055992BD Q44475774-9790D652-F183-4D09-8B61-3E59C0C3464D Q50084116-7F53FC0D-1BBE-40BA-B56D-39CE1B54D2BE Q51054145-C83B4E11-EEC0-40C4-A46F-DBB68AC352A6 Q52672810-8856289F-68DF-4A55-81DE-B67C3EE67660

P2860

Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.

http://www.wikidata.org/entity/Q43228809

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Efficacy of a 6-month versus 9 ...... : a randomized clinical trial.

@en

Efficacy of a 6-month versus 9 ...... : a randomized clinical trial.

@nl

type

label

Efficacy of a 6-month versus 9 ...... : a randomized clinical trial.

@en

Efficacy of a 6-month versus 9 ...... : a randomized clinical trial.

@nl

prefLabel

Efficacy of a 6-month versus 9 ...... : a randomized clinical trial.

@en

Efficacy of a 6-month versus 9 ...... : a randomized clinical trial.

@nl

P1433

Q43228809-75AA977D-8122-4DD9-8E4C-D2D4C1ACAEF7

P1476

Q43228809-3F189866-933D-4274-B123-9586834E043B

P2093

Q43228809-0FEC703F-FBE1-4EDD-95B3-7A69931F91A9

Q43228809-166F7F27-9C9C-43A0-A48A-498CF87ACC5D

Q43228809-29B47770-E689-4F23-AB9E-6451A23EC6B2

Q43228809-3A503546-4574-4A1A-A82A-9D35417A9817

Q43228809-519C29EE-24CF-4A2C-80DD-ACED25CE6F46

Q43228809-5878C6CB-142A-4DB3-A797-C695AA62F5FF

Q43228809-68AE5BE4-5183-4A9F-8F30-07330155F74D

Q43228809-7C076002-4356-4971-87BD-78B96A6143DE

Q43228809-9A1FA998-7BC5-410D-BF81-3C9D588235D9

Q43228809-D7C0D545-98C0-4F4A-8FD9-AEDA60DD9193

P2860

Q43228809-097A2D57-7495-4DDE-A970-63CAA615A030

Q43228809-13EDC953-91BA-4BA2-8A3D-6F0E2C82A022

Q43228809-21C09424-B209-4937-A5FA-A884B80901B3

Q43228809-2205BE6C-B641-4BCC-BF04-770BAC7CFCD4

Q43228809-243D1BCA-C05A-47DA-BB48-D8D530705BE8

Q43228809-40BD585C-79A0-4CF9-8B94-413962634392

Q43228809-46D6DF5C-C855-4BD5-930F-F61FB06C3D84

Q43228809-5C64900F-4785-45BB-8244-915953F15FA7

Q43228809-5D14BDD3-F3FA-4C32-B5D7-EB5C41A34CAB

Q43228809-71C1F547-6ECA-4EF1-98E2-059CAE9C488D

P304

Q43228809-F8541E43-86FA-44C2-AD3D-96BA14CB3307

P31

Q43228809-D5657FB9-5848-4C02-B2A2-33164D70B9DE

P356

Q43228809-BB192AA3-F90A-40DC-8E82-3C310057D500

P407

Q43228809-1F898E64-9CAE-440E-BA52-E548C41CF3BD

P433

Q43228809-0F3174B6-3693-4DFD-AD8C-5121471E9D7A

P478

Q43228809-94D1B760-47F4-4350-8A1D-40FB178DF920

P50

Q43228809-EC891799-B951-45BF-899D-CBC2A24F7EAA

P577

Q43228809-ACFC79F2-585F-4061-A472-BC986C5BF3BF

P698

Q43228809-AA9651B9-090C-4132-A06B-BEB5549F37D0

P921

Q43228809-D36D1A0F-E0EF-453C-94C3-AEC8146287D5

P356

RCCM.200903-0439OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Efficacy of a 6-month versus 9 ...... : a randomized clinical trial.

@en

P2093

Chandrasekharan Padmapriyadarsini

http://www.w3.org/2001/XMLSchema#string

Gopalan Narendran

http://www.w3.org/2001/XMLSchema#string

Mohanarani Suhadev

http://www.w3.org/2001/XMLSchema#string

Paranji R Narayanan

http://www.w3.org/2001/XMLSchema#string

Perumal Venkatesan

http://www.w3.org/2001/XMLSchema#string

Ponnuraja Chinnaiyan

http://www.w3.org/2001/XMLSchema#string

Pradeep Aravindan Menon

http://www.w3.org/2001/XMLSchema#string

Raja Sakthivel

http://www.w3.org/2001/XMLSchema#string

Rameshkumar Santhanakrishnan

http://www.w3.org/2001/XMLSchema#string

Ranjani Ramachandran

http://www.w3.org/2001/XMLSchema#string

P2860

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

The growing burden of tuberculosis: global trends and interactions with the HIV epidemic

Treatment Options for HIV-Associated Tuberculosis.

A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes.

Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1.

Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review.

Treatment outcomes of patients with HIV and tuberculosis.

Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection.

Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis.

Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease

P304

743-751

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.200903-0439OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

181

http://www.w3.org/2001/XMLSchema#string

P50

Soumya Swaminathan

P577

2009-12-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19965813

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde